A detailed history of Goldman Sachs Group Inc transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 153,554 shares of DCTH stock, worth $1.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
153,554
Previous 123,487 24.35%
Holding current value
$1.9 Million
Previous $1.57 Million 32.91%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$10.39 - $18.1 $312,396 - $544,212
30,067 Added 24.35%
153,554 $2.09 Million
Q1 2025

May 09, 2025

BUY
$11.43 - $16.45 $522,293 - $751,682
45,695 Added 58.74%
123,487 $1.57 Million
Q4 2024

Feb 11, 2025

BUY
$8.32 - $12.64 $480,346 - $729,757
57,734 Added 287.84%
77,792 $916,000
Q3 2024

Nov 14, 2024

SELL
$7.36 - $11.0 $139,869 - $209,044
-19,004 Reduced 48.65%
20,058 $181,000
Q2 2024

Aug 13, 2024

BUY
$4.47 - $8.37 $174,607 - $326,948
39,062 New
39,062 $326,000

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $106M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.